- Home
- LUNG vs BDTX Comparison
LUNG vs BDTX Comparison
Compare LUNG & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- BDTX
- Stock Information
- Founded
- LUNG 1995
- BDTX 2014
- Country
- LUNG United States
- BDTX United States
- Employees
- LUNG N/A
- BDTX N/A
- Industry
- LUNG Industrial Specialties
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LUNG Health Care
- BDTX Health Care
- Exchange
- LUNG Nasdaq
- BDTX Nasdaq
- Market Cap
- LUNG 124.0M
- BDTX 132.5M
- IPO Year
- LUNG 2020
- BDTX 2020
- Fundamental
- Price
- LUNG $2.78
- BDTX $2.58
- Analyst Decision
- LUNG Buy
- BDTX Strong Buy
- Analyst Count
- LUNG 6
- BDTX 6
- Target Price
- LUNG $11.53
- BDTX $14.83
- AVG Volume (30 Days)
- LUNG 311.3K
- BDTX 1.3M
- Earning Date
- LUNG 07-30-2025
- BDTX 08-05-2025
- Dividend Yield
- LUNG N/A
- BDTX N/A
- EPS Growth
- LUNG N/A
- BDTX N/A
- EPS
- LUNG N/A
- BDTX 0.09
- Revenue
- LUNG $87,473,000.00
- BDTX $70,000,000.00
- Revenue This Year
- LUNG $18.02
- BDTX N/A
- Revenue Next Year
- LUNG $18.17
- BDTX N/A
- P/E Ratio
- LUNG N/A
- BDTX $29.29
- Revenue Growth
- LUNG 19.84
- BDTX N/A
- 52 Week Low
- LUNG $2.50
- BDTX $1.20
- 52 Week High
- LUNG $9.37
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- LUNG 41.83
- BDTX 60.65
- Support Level
- LUNG $2.52
- BDTX $2.43
- Resistance Level
- LUNG $2.84
- BDTX $2.72
- Average True Range (ATR)
- LUNG 0.16
- BDTX 0.18
- MACD
- LUNG 0.04
- BDTX -0.00
- Stochastic Oscillator
- LUNG 46.36
- BDTX 76.11
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.